Recent Updates
Recently added Catalysts
RCUS Positive Sentiment

Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London

Monday, November 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arcus Biosciences will participate in the Jefferies Global Healthcare Conference in London. The management team is scheduled for a fireside chat on November 16th, 2026, at 5:00pm GMT. A live webcast of the presentation will be available for interested parties.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arcus Biosciences is actively engaging with investors.
  • Participation in a major healthcare conference highlights company visibility.
  • Management's presence indicates confidence in their pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
2.8%
average across 10 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
Etrumadenant
Phase 1 · Prostatic Neoplasms, Castration-Resistant

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, announced that its management team will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London, UK. The fireside chat will take place on Monday, November 16th, 2026, at 5:00pm GMT. A live webcast of the presentation will

Frequently Asked Questions

When is the Jefferies Global Healthcare Conference?

The conference is on November 16th, 2026, at 5:00pm GMT.

Where will the conference take place?

It will be held in London, UK.

What will Arcus Biosciences present?

They will participate in a fireside chat during the conference.

Will there be a webcast of the presentation?

Yes, a live webcast of the presentation will be available.

ShareAdd on Google
Tags: RCUS Arcus Biosciences Jefferies Global Healthcare Conference biopharmaceuticals cancer therapies
Last updated: Nov 2, 2026

Biotech snapshot

Cash runway
$775M liquidity · $40M/mo burn
~17 mo
Low dilution risk
Lead asset
EtrumadenantPhase 1
Prostatic Neoplasms, Castration-Resistant →

Catalyst track record

+65%
best trade around RCUS's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for RCUS.

See every catalyst's timing & PoA →